Recombinant Human NAGA Protein，His

NAGA, or N-acetylgalactosamine-6-sulfatase, is an essential enzyme involved in the lysosomal degradation of glycosaminoglycans, specifically heparan sulfate and dermatan sulfate. Deficiencies in NAGA are linked to a rare genetic disorder known as Morquio A syndrome, which results in skeletal abnormalities, organ dysfunction, and reduced mobility. Research on NAGA recombinant proteins aims to provide insights into the enzyme's structure and function, as well as potential therapeutic interventions for affected individuals. By producing NAGA in a recombinant system, researchers can overcome limitations associated with natural enzyme extraction, such as low yield and potential contamination. These recombinant proteins can also serve as valuable tools for studying the enzyme's activity, substrate specificity, and interaction with other lysosomal enzymes. Furthermore, the development of recombinant NAGA may pave the way for enzyme replacement therapies, offering hope for patients with Morquio A syndrome by restoring the missing enzyme activity and improving the overall pathology associated with the disorder. This line of research not only contributes to understanding lysosomal storage disorders but also opens avenues for developing innovative treatments that enhance patients' quality of life.